Symptomatic melanoma CNS metastases in the TRICOTEL study

In this cohort, an objective response rate of 58% (95% CI 37–78) was achieved with triple therapy, which is about what would be expected for BRAF/MEK inhibitor treatment.2 However, the reported duration of response of 9·9 months (95% CI 4·8–12·7) significantly outperformed other treatment strategies, especially combined immunotherapy or BRAF/MEK inhibitor treatment,2,3 and was even better than the duration of response for the cohort of asymptomatic patients in the same study. For two patients, LDH increased, and for two patients, pain of melanoma lesion (thoracic, pelvic and retrosacral) and tumour abdominal pain are reported as brain-related symptoms. JL has received honoraria from Eisai, Novartis, Incyte, Merck, touchIME, touchEXPERTS, Pfizer, the Royal College of Physicians, Cambridge Healthcare Research, the Royal College of General Practitioners, VJOncology, Agence Unik, and Bristol Myers Squibb; consultancy fees from iOnctura, Apple Tree, Merck, Bristol Myers Squibb, Eisai, Debipharm, and Incyte; speaker fees from Pierre Fabre, Bristol Myers Squibb, Ipsen, Roche, EUSA Pharma, Novartis, Aptitude, AstraZeneca, GlaxoSmithKline, Eisai, Calithera, Ultimovacs, Seagen, Merck, eCancer, MCA, Inselgruppe, Pfizer, Goldman Sachs, and MSD; institutional research support from Bristol Myers Squibb, MSD, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics, and Aveo; and grants from Achilles, Bristol Myers Squibb, MSD, Nektar, Novartis, Pfizer, Roche, Immunocore, Aveo, and Pharmacyclics.